Relief Therapeutics Holding Company Description
Relief Therapeutics Holding SA, a biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases.
The company offers SETOFILM/ONDISSOLVE for nausea and vomiting associated with radiotherapy-induced, chemotherapy, and postoperative sequels; ACER-001, a sodium phenylbutyrate for the treatment of urea cycle disorders; and PKU GOLIKE for the dietary management of phenylketonuria.
It also develops RLF-100, a synthetic form of vasoactive intestinal peptide for the treatment of acute respiratory distress syndrome and certain chronic lung diseases, including sarcoidosis, berylliosis, and checkpoint inhibitor-induced pneumonitis.
In addition, the company develops RLF-TD011, a hypochlorous acid solution for epidermolysis bullosa. Further, it is developing RLF-OD32, a next-generation liquid sapropterin formulation for phenylketonuria.
The company operates in Switzerland, Europe, North America, and internationally. Relief Therapeutics Holding SA was founded in 2013 and is based in Geneva, Switzerland.
| Country | Switzerland |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 31 |
Contact Details
Address: Avenue de Secheron 15 Geneva, 1202 Switzerland | |
| Website | relieftherapeutics.com |
Stock Details
| Ticker Symbol | RLFTY |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| ISIN Number | CH1251125998 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Giorgio Reiner | Chief Scientific Officer |
| Paolo Galfetti | Chief Business Officer |